Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
|Articles|April 27, 2016
BARDA Innovation Initiatives in Medical Countermeasure Manufacturing
Advertisement
Keynote SeriesPharmaceutical Technology and BioPharm International are sponsoring a Keynote Series session on strategies and innovations to reduce drug shortages and improve availability of medicines on the INTERPHEX 2016 Exhibit Hall Innovation Stage. Admission is free to any attendee with an exhibit hall pass.
Wednesday, April 27
1:30–3:15 pm
Strategies and Innovations to Reduce Drug Shortages and Improve Availability of Medicines
Aging facilities and equipment, inadequate operator training, a lack of quality control, tighter regulatory enforcement, and business decisions to eliminate unprofitable product lines contribute to ongoing shortages vital drug products. In this session, industry thought leaders will identify triggers for drug shortages, methods to avoid production line shutdowns and update facilities, and innovative industry efforts to fulfill demand for needed therapies. A Q&A session will follow the presentations.
2-2:30 pm
BARDA Innovation Initiatives in Medical Countermeasure Manufacturing
This presentation will describe the Biomedical Advanced Research and Development Authority’s (BARDA) program initiatives in manufacturing technologies for medical countermeasure advanced development. Opportunities with the Centers for Innovation in Advanced Development & Manufacturing (CIADMs) and in Continuous Manufacturing will be discussed.
Speakers:
Michael Angelastro, Deputy Director for Manufacturing, Facilities and Engineering, Biomedical Advanced Research and Development Authority (BARDA)
Kimberly Sciarretta, PhD, Anti-Infectives (AI) Program, Division of CBRN Countermeasures, Biomedical Advanced Research and Development Authority (BARDA)
To register:
Other presentations in this session:
1:30–2 pm
2:30-3 pm
Advertisement
Related to this article
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Advertisement
Advertisement